# A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers

> **NCT07502534** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 180 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** IBI3027
- **DRUG:** DUPIXENT® (dupilumab)

## Key facts

- **NCT ID:** NCT07502534
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-04-24
- **Primary completion:** 2026-07-07
- **Final completion:** 2026-07-07
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502534, "A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT07502534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*